An interventional study of Skin biopsy in Retinal Dystrophies, sponsored by University Hospital, Montpellier. Completed at 1 site in France. Open to participants aged 5 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Other
The investigators are focused on inherited retinal dystrophies with an aim to further understand disease pathophysiology and to elaborate novel treatments, as, to date, there is no effective treatment to prevent blindness.
The main goal of this study is to generate human cellular models of healthy and disease retinas and perform studies to evaluate the efficiency of gene therapy approaches for different diseases.
Skin biopsies of volunteers are cultured to isolate fibroblasts that are then reprogrammed into iPS cells. Healthy and disease-specific iPS cells are then differentiated into retinal models.
This study should help to elucidate disease pathways and to provide proof-of-concept for various therapeutic approaches.
56 studies on the registry are indexed under Retinal Dystrophies; 16 are open to participants now.
This study's planned enrollment of 150 is above the median of 21 across 32 interventional studies indexed under Retinal Dystrophies.
Browse Retinal Dystrophies studies →University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 224 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Choroideremia :
And in all cases or pattern
Exclusion criteria :
Other: Skin biopsy
Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
number of human cell models obtained
Time frame: 10 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier